Latest & greatest articles for Osteosarcoma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Osteosarcoma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Osteosarcoma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Osteosarcoma

1. Osteosarcoma

Osteosarcoma Osteosarcoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteosarcoma Last reviewed: February 2019 Last updated: February 2019 Summary Most common non-haematological primary malignant neoplasm of bone in children and adolescents. Pain and swelling are the most common presenting symptoms. Although it can occur at any age, it usually affects patients in the second and third decade of life with a peak (...) incidence between 13 and 16 years of age. It is more common in males than females. Chemotherapy combined with surgery is the standard of care. Prognosis of patients with localised disease has improved substantially following the introduction of chemotherapy, with 75% to 80% 5-year survival rates. Definition The World Health Organization defines osteosarcoma as a primary osseous malignant neoplasm composed of mesenchymal cells producing osteoid and immature bone, even if only in small amounts. Fletcher

2019 BMJ Best Practice

2. Osteosarcoma treatment outcomes during pregnancy: a systematic review and case report

Osteosarcoma treatment outcomes during pregnancy: a systematic review and case report Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

3. Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives (PubMed)

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology. The current standard care for high-grade OS treatment is neoadjuvant chemotherapy, followed by surgery and post-operative chemotherapy. In order to ameliorate survival rates of patients, new

Full Text available with Trip Pro

2018 Biomedicines

4. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center (PubMed)

Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center Metastatic osteosarcoma is largely treated with high-dose methotrexate (HDMTX)-based therapy, especially in the pediatric population. This mandates complex pharmacokinetic monitoring in a costly inpatient setting to mitigate unpredictable serious toxicities. Hence, a non-HDMTX-based (...) regimen is worth exploring, especially in India and low- and middle-income countries.All consecutive treatment-naïve patients with metastatic osteosarcoma were prospectively treated on the novel OGS-12 protocol consisting of sequential doublets of doxorubicin, cisplatin, and ifosfamide. Four cycles were administered as neoadjuvant therapy followed by planned curative intent surgery and metastasectomy when feasible, followed by four cycles of adjuvant chemotherapy. Baseline characteristics, histologic

Full Text available with Trip Pro

2018 Journal of global oncology

5. MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma (PubMed)

MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma MicroRNAs (miRNAs) have been widely reported to have important regulatory roles in various human tumors, including osteosarcoma (OS). The aim of this study was to focus on the role of less well-known miRNA-567 (miR-567) in OS. We found the expression of miR-567 was significantly reduced in OS tissues and cell lines (MG-63, U2OS and Saos-2) compared with the adjacent normal tissues and normal

Full Text available with Trip Pro

2018 EXCLI journal

6. The Team Approach to Osteosarcoma of the Distal Femur in an Adolescent (PubMed)

The Team Approach to Osteosarcoma of the Distal Femur in an Adolescent 29278618 2018 11 13 2329-9185 5 12 2017 Dec JBJS reviews JBJS Rev Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents. e5 10.2106/JBJS.RVW.17.00030 Stitzlein Russell N RN Departments of Orthopaedic Surgery (R.N.S. and K.L.W.), Pathology and Laboratory Medicine (J.W.), Radiology (R.A.S.), and Pediatrics (N.J.B.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. Wojcik John J

Full Text available with Trip Pro

2017 JBJS reviews

7. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review. (PubMed)

Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review. Osteosarcoma mostly occurs during the period of rapid bone growth in children and adolescents as high-grade osteosarcomas. Current treatment recommended for high-grade non-metastatic and metastatic and/or relapsed osteosarcoma involves neoadjuvant multiagent conventional chemotherapy, followed by surgical resection of macroscopically detected tumor and postoperative adjuvant (...) chemotherapy. However, residual micrometastatic deposits that develop following surgery have shown resistance to postoperative/adjuvant chemotherapy. Therefore, there is a critical need for more effective and innovative therapeutic approaches such as immune stimulatory agents. The most extensively studied immune stimulatory agent in the treatment of osteosarcoma is mifamurtide. The aim of this systematic review was to identify and synthesize the evidence on the effectiveness of mifamurtide in addition

2017 JBI database of systematic reviews and implementation reports

8. MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1 (PubMed)

MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1 MiR-429 functions as a tumor suppressor and has been observed in multiple types of cancer, but the effects and mechanisms of miR-429 in osteosarcoma are poorly understood. This study is performed to evaluate the functions of miR-429 in the progression of osteosarcoma. Firstly, the miR-429 expression in osteosarcoma tissues and osteosarcoma cells was detected using real time PCR, and the relationship between miR (...) -429 expression and overall survival of osteosarcoma was analyzed. Secondly, the effects of miR-429 on the migration, invasion, proliferation and apoptosis of osteosarcoma cells were evaluated using transwell assay, wound-healing assay, CCK-8 assay and flow cytometry, respectively. Proteins related to epithelial-mesenchymal transition (EMT), E-cadherin, Vimentin, N-cadherin and Snail, were also detected using Western blot. Finally, the target gene of miR-429 in osteosarcoma was predicted

Full Text available with Trip Pro

2017 EXCLI journal

9. Unique Image Characteristics of an Occipital Primary Chondroblastic Osteosarcoma: A Rare Case Report and a Brief Literature Review (PubMed)

Unique Image Characteristics of an Occipital Primary Chondroblastic Osteosarcoma: A Rare Case Report and a Brief Literature Review Primary osteosarcomas of the skull and skull base are rare and comprise < 2% of all skull tumors. In head and neck osteosarcomas, the chondroblastic subtype occurs most frequently, which has an exceedingly poor outcome, but its image characteristic remains unknown. Herein, we report a case in the right occipital bone of the skull base and the unique characteristics (...) of image. Pathologic examination of the surgical specimens led to the diagnosis of chondroblastic osteosarcomas. We believe those image characteristics can improve the understanding of skull chondroblastic osteosarcoma and the preoperative diagnosis.

Full Text available with Trip Pro

2017 Journal of neurological surgery reports

10. GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma: A meta-analysis. (PubMed)

GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma: A meta-analysis. The association between GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma is controversial according to previously published studies. We conducted this meta-analysis to further investigate the role of GSTP1 A>G genetic variation in response to chemotherapy resistance in patients with osteosarcoma. Using the electronic databases of Pubmed, Wanfang and CNIK were searched to find the studies related (...) to the GSTP1 A>G polymorphism and chemosensitivity of osteosarcoma. The genotype of AA, AG and GG were extracted from the chemotherapy sensitivity and chemotherapy resistance group. The association between GSTP1 A>G polymorphism and chemosensitivity was calculated by STATA11.0 software. The correlation between GSTP1 A>G polymorphism and chemotherapy response was assessed by odds ratio (OR) and its 95% confidence interval (95%CI). Four studies with 681 cases were finally included in this meta-analysis

Full Text available with Trip Pro

2017 Open medicine (Warsaw, Poland)

11. Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources (PubMed)

Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources Health-related quality of life (HRQOL) improves throughout treatment of patients with nonmetastatic osteosarcoma. We compared HRQOL for patients in the United States and Chile treated on an international trial (OS99) with polychemotherapy and surgery, and we assessed the relationships among HRQOL measures, event-free survival (EFS), and overall (...) survival (OS).Patients with newly diagnosed, localized osteosarcoma and their parents completed three HRQOL instruments (PedsQL v.4, PedsQL Cancer v.3, and Symptom Distress Scale [SDS]). Data were collected at four time points throughout therapy. Repeated measures models were used to investigate the effect of treatment site on instrument scores. The log-rank test examined the impact of treatment site on survival outcomes, and Cox proportional hazards regression models evaluated baseline HRQOL measures

Full Text available with Trip Pro

2017 Journal of global oncology

12. Chemotherapy in Nonmetastatic Osteosarcoma: Recent Advances and Implications for Developing Countries (PubMed)

Chemotherapy in Nonmetastatic Osteosarcoma: Recent Advances and Implications for Developing Countries Osteosarcoma (OS) is a relatively chemosensitive primary bone tumor, with the peak age of onset occurring in late childhood and early adolescence. The treatment paradigm of nonmetastatic OS has typically been multimodality therapy, including neoadjuvant and adjuvant chemotherapy with definitive surgery. Over the years, various permutations and combinations of chemotherapeutic agents have been

Full Text available with Trip Pro

2017 Journal of global oncology

14. Osteosarcoma

Osteosarcoma Osteosarcoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteosarcoma Last reviewed: February 2019 Last updated: February 2019 Summary Most common non-haematological primary malignant neoplasm of bone in children and adolescents. Pain and swelling are the most common presenting symptoms. Although it can occur at any age, it usually affects patients in the second and third decade of life with a peak (...) incidence between 13 and 16 years of age. It is more common in males than females. Chemotherapy combined with surgery is the standard of care. Prognosis of patients with localised disease has improved substantially following the introduction of chemotherapy, with 75% to 80% 5-year survival rates. Definition The World Health Organization defines osteosarcoma as a primary osseous malignant neoplasm composed of mesenchymal cells producing osteoid and immature bone, even if only in small amounts. Fletcher

2017 BMJ Best Practice

15. Osteosarcoma Overview (PubMed)

Osteosarcoma Overview Osteosarcoma (OS) is the most common primary malignancy of bone and patients with metastatic disease or recurrences continue to have very poor outcomes. Unfortunately, little prognostic improvement has been generated from the last 20 years of research and a new perspective is warranted. OS is extremely heterogeneous in both its origins and manifestations. Although multiple associations have been made between the development of osteosarcoma and race, gender, age, various

Full Text available with Trip Pro

2016 Rheumatology and therapy

16. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma.EURAMOS-1 was an open-label (...) , international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial

Full Text available with Trip Pro

2016 EvidenceUpdates

17. Review of Osteosarcoma and Current Management (PubMed)

Review of Osteosarcoma and Current Management Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical

Full Text available with Trip Pro

2016 Rheumatology and therapy

18. Gnathic Osteosarcoma: Clinical, Radiologic, and Pathologic Review of Bone Beard Tumor (PubMed)

Gnathic Osteosarcoma: Clinical, Radiologic, and Pathologic Review of Bone Beard Tumor 29244987 2019 01 14 2019 01 14 2378-9506 3 6 2017 12 Journal of global oncology J Glob Oncol Gnathic Osteosarcoma: Clinical, Radiologic, and Pathologic Review of Bone Beard Tumor. 823-827 10.1200/JGO.2016.006494 Mahajan Abhishek A All authors: Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India. Vaish Richa R All authors: Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra (...) 101674751 2378-9506 IM Breast Neoplasms diagnosis pathology surgery Carcinoma, Ductal, Breast diagnosis pathology surgery Female Humans Jaw Neoplasms diagnosis surgery Magnetic Resonance Imaging Middle Aged Osteosarcoma diagnosis surgery Tomography, X-Ray Computed 2017 12 16 6 0 2017 12 16 6 0 2019 1 15 6 0 ppublish 29244987 10.1200/JGO.2016.006494 PMC5735964 J Clin Oncol. 1997 Jan;15(1):363-7 8996163 J Oral Maxillofac Surg. 2011 Sep;69(9):2368-75 21288615 Med Oncol. 2014 Sep;31(9):171 25134917 Head

Full Text available with Trip Pro

2016 Journal of global oncology

19. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 (PubMed)

Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity.Patients age ≤ 40 years randomly received regimens with the same cumulative doses of drugs (ADM 420 mg/m(2

2012 EvidenceUpdates

20. Methotrexate for high-grade osteosarcoma in children and young adults. (PubMed)

Methotrexate for high-grade osteosarcoma in children and young adults. The majority of the currently used treatment protocols for osteosarcoma are based on a combination of doxorubicin, cisplatin, methotrexate (MTX) and/or ifosfamide, of which MTX seems to be one of the most active drugs. However, in the literature, this has not been unambiguously proven.To compare the effectiveness of treatment including MTX with treatment without MTX for children and young adults (up to 21 years) with primary (...) can be made about the effects on antitumour efficacy, toxicities and quality of life of the addition of MTX to treatment of children and young adults with primary high-grade osteosarcoma. The same is true for combinations of treatment including and not including MTX other than treatment with MTX versus treatment with cisplatin. Only 1 RCT comparing MTX with cisplatin treatment was available and therefore, no definitive conclusions can be made about the effectiveness of these agents in children

2011 Cochrane